New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
AbbVie is presenting 22 scientific abstracts from its IBD portfolio at the ACG 2026 Annual Scientific Meeting, including new Phase 3 AFFIRM results for subcutaneous SKYRIZI in Crohn's disease. AFFIRM showed significantly higher rates of clinical remission and endoscopic response versus placebo at Week 12, and an indirect comparison showed SKYRIZI beating guselkumab on endoscopic response during induction. Long-term extension data (FORTIFY, SEQUENCE, COMMAND) show sustained outcomes up to 144-148 weeks, and real-world VA and DoD data support RINVOQ in difficult-to-treat Crohn's disease.
Key figures
- Drug Name
- SKYRIZI (risankizumab-rzaa); RINVOQ (upadacitinib)
- Phase Of Trial
- Phase 3
- Abstracts presented
- 22
- Dod ileal cd 6mo clinical remission
- 57%
- Va real world fistulizing remission
- 93.3%
- Va real world stricturing remission
- 76.9%
- Fistulizing cd no draining fistulas 5yr
- 74.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.